Archives for April 2011

Comments to Lee et al: Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.

Diabetes 60:391-397, 2011.
Accumulating evidence during the last several decades has suggested that glucagon is of key importance for diabetes hyperglycemia. Thus, patients with type 2 diabetes have hyperglucagonemia and increased hepatic glucose output, and the hyperglycemia seems to be caused by a defective suppression of glucagon during hyperglycemia (1). A recent experimental study by Lee and collaborators examined the role of glucagon in mice with type 1 diabetes induced by streptozotin (2). They approached this aim by using a mouse model with genetic deletion of the glucagon receptors. This model …

Comments to Bagger et al: Impaired regulation of the incretin effect in patients with type 2 diabetes.

J Clin Endocrinol Metab 96:737-745 (2011)
The incretin effect is defined as the augmented insulin secretion after oral versus intrave-nous glucose administration and is due to the release from the gut of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) after oral glucose; these incretin hormones augment glucose-stimulated insulin secretion (1). The incretin function is of key importance for normal glucose levels after oral glucose. It has also been shown that the incretin effect is impaired in type 2 diabetes (2). This is mainly due to impaired action …